UBS Group’s VolitionRx Ltd VNRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.97K | Sell |
4,419
-5,953
| -57% | -$14.4K | ﹤0.01% | 8878 |
|
|
2026
Q1 | $41.9K | Buy |
10,372
+10,356
| +64,725% | +$49.5K | ﹤0.01% | 7487 |
|
|
2025
Q4 | $79 | Sell |
16
-725
| -98% | -$5.51K | ﹤0.01% | 10220 |
|
|
2025
Q3 | $10.1K | Buy |
741
+672
| +974% | +$8.94K | ﹤0.01% | 8561 |
|
|
2025
Q2 | $1.05K | Sell |
69
-4,090
| -98% | -$45.1K | ﹤0.01% | 9681 |
|
|
2025
Q1 | $47.4K | Sell |
4,159
-1,208
| -23% | -$14.4K | ﹤0.01% | 7638 |
|
|
2024
Q4 | $64.4K | Sell |
5,367
-423
| -7% | -$5.67K | ﹤0.01% | 7143 |
|
|
2024
Q3 | $69.6K | Buy |
5,790
+2,443
| +73% | +$31.4K | ﹤0.01% | 6599 |
|
|
2024
Q2 | $40.5K | Buy |
3,347
+1,924
| +135% | +$28.2K | ﹤0.01% | 6850 |
|
|
2024
Q1 | $21.5K | Buy |
1,423
+1,282
| +909% | +$25.1K | ﹤0.01% | 6896 |
|
|
2023
Q4 | $2.02K | Buy |
141
+47
| +50% | +$691 | ﹤0.01% | 8177 |
|
|
2023
Q3 | $1.29K | Sell |
94
-451
| -83% | -$11.2K | ﹤0.01% | 7997 |
|
|
2023
Q2 | $15.2K | Buy |
545
+40
| +8% | +$1.32K | ﹤0.01% | 6994 |
|
|
2023
Q1 | $19.3K | Buy |
505
+409
| +426% | +$17.1K | ﹤0.01% | 7110 |
|
|
2022
Q4 | $4.68K | Sell |
96
-810
| -89% | -$31.5K | ﹤0.01% | 9298 |
|
|
2022
Q3 | $24K | Buy |
906
+742
| +452% | +$28.1K | ﹤0.01% | 7161 |
|
|
2022
Q2 | $7K | Sell |
164
-129
| -44% | -$6.5K | ﹤0.01% | 8537 |
|
|
2022
Q1 | $18K | Buy |
293
+199
| +212% | +$11.3K | ﹤0.01% | 7588 |
|
|
2021
Q4 | $6K | Hold |
94
| – | – | ﹤0.01% | 9304 |
|
|
2021
Q3 | $6K | Sell |
94
-86
| -48% | -$5.45K | ﹤0.01% | 8453 |
|
|
2021
Q2 | $11K | Sell |
180
-299
| -62% | -$20.2K | ﹤0.01% | 7983 |
|
|
2021
Q1 | $36K | Sell |
479
-122
| -20% | -$10.5K | ﹤0.01% | 6858 |
|
|
2020
Q4 | $46K | Buy |
601
+357
| +146% | +$24.6K | ﹤0.01% | 6267 |
|
|
2020
Q3 | $15K | Sell |
244
-423
| -63% | -$28.8K | ﹤0.01% | 6538 |
|
|
2020
Q2 | $51K | Buy |
667
+442
| +196% | +$31.9K | ﹤0.01% | 5843 |
|
|
2020
Q1 | $14K | Buy |
225
+142
| +171% | +$11.8K | ﹤0.01% | 6737 |
|
|
2019
Q4 | $8K | Sell |
83
-143
| -63% | -$14.8K | ﹤0.01% | 7405 |
|
|
2019
Q3 | $25K | Buy |
226
+101
| +81% | +$8.04K | ﹤0.01% | 6610 |
|
|
2019
Q2 | $8K | Buy |
125
+42
| +51% | +$2.72K | ﹤0.01% | 7204 |
|
|
2019
Q1 | $5K | Sell |
83
-85
| -51% | -$4.75K | ﹤0.01% | 7188 |
|
|
2018
Q4 | $6K | Sell |
168
-766
| -82% | -$36.5K | ﹤0.01% | 7493 |
|
|
2018
Q3 | $48K | Buy |
934
+834
| +834% | +$34.3K | ﹤0.01% | 6191 |
|
|
2018
Q2 | $4K | Sell |
100
-149
| -60% | -$6.66K | ﹤0.01% | 7568 |
|
|
2018
Q1 | $12K | Sell |
249
-160
| -39% | -$9.36K | ﹤0.01% | 6767 |
|
|
2017
Q4 | $24K | Buy |
409
+276
| +208% | +$16.2K | ﹤0.01% | 6415 |
|
|
2017
Q3 | $7K | Sell |
133
-133
| -50% | -$7.81K | ﹤0.01% | 7086 |
|
|
2017
Q2 | $19K | Buy |
266
+87
| +49% | +$6.28K | ﹤0.01% | 6346 |
|
|
2017
Q1 | $14K | Buy |
+179
| New | +$15.8K | ﹤0.01% | 6413 |
|
|
2016
Q4 | – | Sell |
-50
| Closed | -$5K | – | 8064 |
|
|
2016
Q3 | $5K | Sell |
50
-130
| -72% | -$10.1K | ﹤0.01% | 7136 |
|
|
2016
Q2 | $11K | Sell |
180
-210
| -54% | -$14.5K | ﹤0.01% | 6734 |
|
|
2016
Q1 | $28K | Buy |
390
+261
| +202% | +$19.6K | ﹤0.01% | 5949 |
|
|
2015
Q4 | $12K | Sell |
129
-298
| -70% | -$25.3K | ﹤0.01% | 7182 |
|
|
2015
Q3 | $38K | Buy |
427
+206
| +93% | +$15.8K | ﹤0.01% | 6072 |
|
|
2015
Q2 | $17K | Buy |
221
+89
| +67% | +$6.73K | ﹤0.01% | 7031 |
|
|
2015
Q1 | $11K | Buy |
+132
| New | +$10.9K | ﹤0.01% | 7575 |
|
Other funds holding VNRX
VCM
WANY
VFT
SBCM
TRCT
AAP
UBS Group's VNRX Position: Q2 2026 in Review
UBS Group reduced its VolitionRx Ltd (VNRX) stake by 57% in Q2 2026, selling an estimated $14.4K and leaving 4,419 shares worth $5.97K. The position accounts for ﹤0.01% of the portfolio, ranked #8878.
UBS Group first reported a position in VNRX in Q1 2015 and has held it in 45 quarters since. The position peaked at $69.6K in Q3 2024. 19 funds tracked by Wall St. Rank hold VNRX as of Q2 2026.
- UBS Group held 4,419 shares of VolitionRx Ltd worth $5.97K as of Q2 2026.
- UBS Group sold 5,953 VolitionRx Ltd shares in Q2 2026, an estimated $14.4K.
- VolitionRx Ltd made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8878 holding.
- UBS Group first reported a position in VolitionRx Ltd in Q1 2015 and has held it in 45 quarters since.
- UBS Group's VolitionRx Ltd position peaked at $69.6K in Q3 2024.
- 19 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.